文献速递垂体与肾上腺疾病

异位库欣综合征的表现、管理与结局:国际多中心回顾性队列研究

Presentation, management, and outcomes of ectopic Cushing syndrome: an international, multicentre, retrospective, cohort study.
PubMed 文献 · Lancet Diabetes Endocrinol · 2026-11-03

BACKGROUND: Ectopic Cushing syndrome is a rare condition with scarce outcome data. We sought to characterise its course and determinants of complications and mortality.…

要点

  • 诊断后6个月内完全生化缓解与晚期并发症和Cushing相关死亡风险降低独立相关。
  • 未在6个月内缓解者并发症和死亡风险显著升高,提示该病为时间关键性内分泌急症。

核心结论

  • 异位库欣综合征的结局由早期控制高皮质醇血症驱动,诊断后6个月内未缓解与并发症和死亡风险显著升高相关。

研究设计与样本

  • 国际多中心回顾性队列研究,纳入亚洲、欧洲、北美、南美和新西兰49个内分泌转诊中心的1463例临床诊断异位库欣综合征患者。
  • 主要结局为研究者裁定的Cushing综合征相关死亡,次要结局为总死亡和并发症发生率。

临床怎么用

  • 应将异位库欣综合征视为时间关键性内分泌急症,力争在诊断后6个月内实现完全生化缓解以降低晚期并发症和死亡风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ectopic Cushing syndrome is a rare condition with scarce outcome data. We sought to characterise its course and determinants of complications and mortality. METHODS: In this international, multicentre, retrospective, cohort study, 49 high-volume endocrine referral centres across Asia, Europe, North America, South America, and New Zealand identified consecutive eligible patients. We included patients with a clinical diagnosis of ectopic Cushing syndrome, defined by expert adjudication at the treating institution with at least one of the following criteria: inferior petrosal sinus sampling or dynamic testing supportive of ectopic Cushing syndrome, biochemical remission of hypercortisolism following treatment of the ectopic Cushing syndrome source (surgical excision, radiotherapy, or cryoablation), evidence of a non-metastatic tumoural source of ectopic Cushing syndrome, either on initial or subsequent imaging, or evidence of a metastatic tumoural source of ectopic Cushing syndrome either on imaging or from chart notes. Data collection was completed between May 31, 2024 and April 22, 2025. Clinical features, biochemical severity, management, complications, and mortality were assessed. The primary outcome was Cushing syndrome-related mortality (investigator-adjudicated). Secondary outcomes were overall mortality and incidence of complications. Outcomes were stratified based on biochemical remission and timeline since diagnosis. Early (within 6 months of diagnosis) and late (>6 months after diagnosis) outcomes were analysed using landmark methods. FINDINGS: Among 1463 patients (median age 51 years [IQR 37-64; range 3-87], 824 [56·3%] women, 639 [43·7%] men, and 1021 [69·8%] of White race), 836 (57·1%) had metastatic disease. Severe hypercortisolism (1204 [91·1%] of 1321) and hypokalaemia (1111 [79·4%] of 1399) were common. Median duration of follow-up was 57 months (IQR 19-124). Cushing syndrome-related death occurred in 196 (13·4%) patients. 626 (42·8%) patients died overall. Infection occurred in 464 (31·7%) patients, venous thromboembolism in 124 (8·5%), cardiovascular events in 93 (6·4%), and cerebrovascular events in 37 (2·5%). Achievement of complete biochemical remission within 6 months of diagnosis was independently associated with lower risk of late complications (adjusted HR 0·55 [95% CI 0·38-0·80]) and Cushing syndrome-related mortality (0·49 [0·27-0·89]), whereas no association was observed with non-Cushing syndrome-related mortality. INTERPRETATION: Outcomes in ectopic Cushing syndrome are driven by early control of hypercortisolism. Failure to achieve remission within 6 months is associated with markedly worse complications and mortality, supporting ectopic Cushing syndrome as a time-critical endocrine emergency. FUNDING: Mayo Clinic.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Chacko SR, Peersen AF, Kaplan JM, et al. Presentation, management, and outcomes of ectopic Cushing syndrome: an international, multicentre, retrospective, cohort study. Lancet Diabetes Endocrinol. 2026. PMID: 42976894. doi:10.1016/S2213-8587(26)00237-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。